Telomere transcripts act as tumor suppressor and are associated with favorable prognosis in colorectal cancer with low proliferating cell nuclear antigen expression
-
Published:2024-09-02
Issue:
Volume:
Page:
-
ISSN:2211-3428
-
Container-title:Cellular Oncology
-
language:en
-
Short-container-title:Cell Oncol.
Author:
Kienzl Philip, Deloria Abigail J., Hunjadi Monika, Hadolt Juliane M., Haering Max-Felix, Bothien Angrit, Mejri Doris, Korkut-Demirbaş Medina, Sampl Sandra, Weber Gerhard, Pirker Christine, Laengle Severin, Braunschmid Tamara, Dragona Eleni, Marian Brigitte, Gagos Sarantis, Lu Lingeng, Henson Jeremy D., Lau Loretta M. S., Reddel Roger R., Mikulits Wolfgang, Stättner Stefan, Holzmann KlausORCID
Abstract
AbstractTelomeric repeat-containing RNAs (TERRA) and telomerase RNA component (TERC) regulate telomerase activity (TA) and thereby contribute to telomere homeostasis by influencing telomere length (TL) and the cell immortality hallmark of cancer cells. Additionally, the non-canonical functions of telomerase reverse transcriptase (TERT) and TERRA appear to be involved in the epithelial-mesenchymal transition (EMT), which is important for cancer progression. However, the relationship between TERRA and patient prognosis has not been fully characterized. In this small-scale study, 68 patients with colorectal cancer (CRC) were evaluated for correlations between telomere biology, proliferation, and EMT gene transcripts and disease outcome. The proliferating cell nuclear antigen (PCNA) and the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) showed a positive correlation with TERRA, while TA and TERRA exhibited an inverse correlation. Consistent with previous findings, the present study revealed higher expression levels of TERT and TERC, and increased TA and TL in CRC tumor tissue compared to adjacent non-tumor tissue. In contrast, lower expression levels of TERRA were observed in tumor tissue. Patients with high TERRA expression and low PCNA levels exhibited favorable overall survival rates compared to individuals with the inverse pattern. Furthermore, TERRA suppressed CRC tumor growth in severe combined immunodeficiency disease (SCID) mice. In conclusion, our study extends previously published research on TERRA suggesting its potential therapeutic role in telomerase-positive CRC.
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Y. Xi, P. Xu, Transl. Oncol. 14, 101174 (2021). https://doi.org/10.1016/j.tranon.2021.101174 2. F. Ciardiello, D. Ciardiello, G. Martini, S. Napolitano, J. Tabernero, A. Cervantes, CA Cancer J. Clin. 72, 372–401 (2022). https://doi.org/10.3322/caac.21728 3. D. Hanahan, R.A. Weinberg, Cell 144, 646–674 (2011). https://doi.org/10.1016/j.cell.2011.02.013 4. J. Wang, X. Zhang, W. Chen, X. Hu, J. Li, C. Liu, Int. J. Cancer 146, 906–916 (2020). https://doi.org/10.1002/ijc.32277 5. K. Gala, E. Khattar, Cancer Lett. 502, 120–132 (2021). https://doi.org/10.1016/j.canlet.2020.12.036
|
|